Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.59 |
| ▸ | ACR | P10323 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13384914 | 1.00 | TP53 (0.61) | TP53PRSS1ACRMAPTALDH1A1 | |
| SCHEMBL12736311 | 1.00 | TP53 (0.61) | TP53PRSS1ACRMAPTALDH1A1 | |
| SCHEMBL11709820 | 0.95 | PRSS1 (0.62) | TP53PRSS1ACRMAPTALDH1A1 | |
| SCHEMBL6864700 | 0.95 | PRSS1 (0.62) | TP53PRSS1ACRMAPTALDH1A1 | |
| SCHEMBL5881227 | 0.88 | THRB (0.61) | TP53PRSS1ACRMAPTALDH1A1 | |
| SCHEMBL12736320 | 0.88 | THRB (0.61) | TP53PRSS1ACRMAPTALDH1A1 | |
| SCHEMBL13867965 | 0.88 | PRSS1 (0.54) | TP53PRSS1ACRALDH1A1CYP1A2 | |
| SCHEMBL25491839 | 0.87 | PRSS1 (0.63) | PRSS1ACRALDH1A1CYP1A2NPC1 | |
| SCHEMBL2741097 | 0.87 | PRSS1 (0.63) | PRSS1ACRALDH1A1CYP1A2NPC1 | |
| SCHEMBL9891377 | 0.87 | PRSS1 (0.63) | PRSS1ACRALDH1A1CYP1A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567522-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| US-9567522-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| US-20130193376-A1 | LIQUID CRYSTAL SYSTEM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-8409469-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8333906-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8129002-B2 | Compounds for use in liquid crystal media | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20120012785-A1 | Liquid Crystal System And Liquid Crystal Display | SCHOTT CECILE (TW) | 2012-01-19 | — | — | US | disclosed |
| US-7914859-B2 | Light modulation media, use in particular for electrooptic displays which are operated at a temperature at which the mesogenic modulation media are in an optically isotropic phase, preferably in a blue phase; reduced operating voltage, reduced temperature dependency of operating voltage, reliability | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| US-20100258763-A1 | LIQUID CRYSTAL SYSTEM AND LIQUID CRYSTAL DISPLAY | SCHOTT CECILE | 2010-10-14 | — | — | US | disclosed |
| US-7794621-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2010-09-14 | — | — | US | disclosed |
| US-20090267025-A1 | LIQUID CRYSTAL SYSTEM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-7531106-B2 | Mesogenic compounds, medium for electro-optical displays and electro-optical display | MERCK PATENT GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-7440160-B2 | Electro-optical light modulating element, electro-optical display and modulating medium | MERCK PATENT GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20080167482-A1 | mesogenic group is linked to the C-atom No. 5 of the 1,3-dioxane-5-yl group; media showing a blue phase and their use in electro-optical light modulation elements | MERCK PATENT GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | CRY1, CRY2, IK | TP53 4159/4885PRSS1 3415/4885ACR 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.